BCIQ Profiles

Company Profile Report
0503 Roivant SPAC
BioCentury & Getty Images


With homegrown pipeline set to reach clinic, Roivant chooses Patient Square’s SPAC as vehicle to NASDAQ

May 3, 2021 | 10:32 PM GMT

A merger between Roivant and a SPAC sponsored by Patient Square will create a publicly traded umbrella company with $2.3 billion to put toward drug discovery, in-licensing and development, including its first program

Read the full 613 word article

How to gain access

Continue reading with a
two-week free trial.